Trials / Completed
CompletedNCT00292487
Patients With Renal Impairment Undergoing CT
Isovue and Visipaque in Renally Impaired Patients Undergoing CT
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- Bracco Diagnostics, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV contrast-enhanced (multidetector computed tomography) MDCT of the liver or MDCT angiography of the lower extremities. Serum Creatinine (SCr) will be measured before and up to 48-72 hours post dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iopamidol 370 mgI/mL |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2006-02-01
- Completion
- 2006-02-01
- First posted
- 2006-02-16
- Last updated
- 2012-02-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00292487. Inclusion in this directory is not an endorsement.